Clinical Trial Detail

NCT ID NCT02845323
Title Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

bladder urothelial carcinoma

Therapies

Urelumab

Nivolumab + Urelumab

Age Groups: adult senior

No variant requirements are available.